October 25, 2014 11:41 PM ET

Pharmaceuticals

Company Overview of Ther-Rx Corporation

Company Overview

Ther-Rx Corporation engages in the development and marketing of specialty women’s healthcare products. It offers Makena, a prescription hormone medicine (progestin) and a hydroxyprogesterone caproate injection that is used to lower the risk of preterm birth in women who are pregnant with one baby and who have delivered one baby too early (preterm) in the past; and Clindesse, a single-dose treatment for non-pregnant women with bacterial vaginosis. The company also provides Evamist (estradiol transdermal spray), an estrogen spray to reduce moderate-to-severe hot flashes caused by menopause; and Gynazole-1 vaginal cream to offer relief in to non-pregnant women with vulvovaginal candidiasis. In ...

One Corporate Woods Drive

Bridgeton, MO 63044

United States

Founded in 1998

Phone:

314-646-3700

Fax:

314-646-3701

Key Executives for Ther-Rx Corporation

President
Age: 47
Compensation as of Fiscal Year 2014.

Ther-Rx Corporation Key Developments

Ther-Rx Corporation Announces Availability of Treatment for Bacterial Vaginosis

Ther-Rx Corporation has announced the availability of Clindesse Vaginal Cream, 2% indicated for the treatment of bacterial vaginosis in non-pregnant women.

Ther-Rx Corporation and Perrigo Co. Announce the Availability of Gynazole-1 (Butoconazole Nitrate Vaginal Cream Usp, 2%) for Prescribing

Ther-Rx Corporation and Perrigo Co. announced that Gynazole-1 (Butoconazole Nitrate Vaginal Cream USP, 2%), indicated for the local treatment of yeast infections (vulvovaginal candidiasis infections caused by Candida) in non-pregnant women, is now available for prescribing. Gynazole-1 is available at major national and regional retail pharmacy chains across the country. Ther-Rx has partnered with Perrigo to manufacture Gynazole-1. Perrigo is a manufacturer of prescription drugs in the U.S. market that has been inspected and approved by the U.S. Food and Drug Administration (FDA) as being in compliance with current Good Manufacturing Practice requirements to manufacture Gynazole-1. Gynazole-1 (Butoconazole Nitrate Vaginal Cream USP, 2%) is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida). The diagnosis should be confirmed by KOH smears and/or cultures.

Similar Private Companies By Industry

Company Name Region
Blansett Pharmacal Company, Inc. United States
HMGene, Inc. United States
OcuCure Therapeutics, Inc. United States
PatentHEALTH, LLC United States
Cystic Fibrosis Foundation Therapeutics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ther-Rx Corporation, please visit www.ther-rx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.